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Genetic tests often identify variants whose significance cannot be 
determined at the time they are reported. In many situations, it is 
critical that clinicians be informed when new information emerges 
on these variants. It is already extremely challenging for laboratories 
to provide these updates. These challenges will grow rapidly as an 
increasing number of clinical genetic tests are ordered and as the 
amount of patient DNA assayed per test expands; the challenges will 
need to be addressed before whole-genome sequencing is used on a 
widespread basis.
Information technology infrastructure can be useful in this con-
text.  We  have  deployed  an  infrastructure  enabling  clinicians 
to  receive  knowledge  updates  when  a  laboratory  changes  the 
classification of a variant. We have gathered statistics from this 
deployment regarding the frequency of both variant classification 
changes and the effects of these classification changes on patients. 
We report on the system’s functionality as well as the statistics 
derived from its use.
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intROdUctiOn
Rapidly falling DNA sequencing costs are generating consider-
able excitement in many fields.1 In the area of clinical medi-
cine, these cost reductions are making it economically feasible 
to decrease the cost of sequencing-based diagnostic tests while 
increasing the portion of patient DNA covered in each test. 
However, as sequencing technology advances there is a grow-
ing realization that geneticists, genetic counselors, physicians, 
and other health-care providers will face increasing challenges 
in managing and applying these results over time. 
Laboratories that conduct sequencing-based tests currently 
encounter considerable challenges when delivering useful inter-
pretive reports. These tests often identify novel genetic variants 
that have not been seen before. In many cases, it is not possible 
to interpret the significance of these variants when they are first 
identified and they become Variants of Unknown Significance 
(VUSs). These VUSs represent a large part of the challenge in 
providing clinically useful reports. 
The identification of a VUS in a patient often makes treat-
ment decisions difficult. For example, in the case of hypertro-
phic cardiomyopathy (HCM), a VUS leaves the provider unable 
to use that information to predict the risk for disease and sud-
den cardiac death in relatives or sometimes results in incorrect 
assumptions and treatment decisions, despite the laboratory’s 
best efforts to write clear reports and recommendations.2 HCM 
is a dominant disease with delayed penetrance and variable 
expressivity;  therefore,  genotype  becomes  critical  to  predict 
who is at risk in the family. Without genotypic information, 
family  members  may  not  pursue  implantable  cardioverter– 
defibrillator placement or other forms of cardiac intervention 
that could save their lives. 
Knowledge of the significance of a VUS often evolves over 
time  as  data  are  accumulated  through  familial  segregation 
studies, control studies, functional analyses, or other means. 
At some point, it becomes possible to provide more informa-
tion about the significance of the variant in diagnostic reports, 
both to the original family and to subsequent families who may 
have the same variant. It is important to ensure that this new 
information is incorporated into future genetic test reports. It is 
also important to provide updated information to providers so 
they can revise patient care plans of previously tested patients. 
In the above HCM example, if a VUS is reclassified to patho-
genic, it enables testing of other family members. For those test-
ing positive, steps can be taken to reduce risk through careful 
monitoring, lifestyle adjustment, and sometimes implantation 
of an implantable cardioverter–defibrillator. For those testing 
negative, repetitive and costly medical evaluations for   family 
  members  can  be  eliminated.  However,  to  impact  care  this 
new clinical information must reach the patient’s health-care 
  provider.
scOPe OF tHe cHALLenGe
Even  for  today’s  clinical  sequencing  tests,  maintaining  and 
communicating  this  information  is  difficult.  It  is  already 
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challenging for laboratories to track the state of clinical knowl-
edge surrounding each variant that can be identified by their 
tests. The Partners HealthCare Center for Personalized Genetic 
Medicine’s Laboratory for Molecular Medicine (LMM) currently 
manages information on 10,155 unique variants known to exist 
in the 219 genes covered by its 183 active clinically orderable 
tests. The LMM uses GeneInsight Lab3 to manage its knowl-
edge base. When a test is first established, the assayed genes are 
defined in the system, which loads reference sequences from 
National Center for Biotechnology Information. Initial variants 
can be loaded into the system from external sources (e.g., data 
downloads from dbSNP or locus-specific databases or manual 
entry from literature curation), but every variant is assessed by 
the LMM and verified by a board-certified geneticist before 
it is incorporated into a patient’s report. Certain benign vari-
ants can be algorithmically assessed but all others are manually 
reviewed. Each time a new variant is identified in a patient, it is 
added to the knowledge base. Because the laboratory’s under-
standing of variants increases over time, every variant is at its 
own stage of its knowledge life cycle. For some, the clinical 
implications are very well understood; others are VUSs and still 
others are in between, where there is some evidence of their 
likely clinical implications but not enough to state these impli-
cations definitively. The LMM’s knowledge base includes 1,958 
(19%) clinically significant variants (pathogenic, likely patho-
genic, resistant, likely resistant, responsive, likely responsive, or 
likely nonresponsive), 1,148 (11%) VUS, 3,188 (31%) incidental 
variants (benign or likely benign), and 3,861 (38%) variants not 
yet classified (not observed during testing but reported in the 
literature or in online databases for the genes tested in the lab). 
Knowledge surrounding these variants can evolve in different 
ways. In addition to knowledge being generated to update the 
classification of a VUS, at times contradictory evidence can 
emerge that necessitates changing the classification of a variant 
that was previously thought to be well understood. 
To date, there has been no clear statement as to who is respon-
sible for staying up to date on the implications of a patient’s 
genetic profile: current guidelines suggest in most cases that the 
process should rely on a combination of effort by the patient 
and primary care physician, with recommendations for future 
inquiry suggested by the medical geneticist at the time of the 
original consultation.4 However, in the case of novel sequence 
variants guidelines suggest the laboratory should make an effort 
to contact the treating clinician.5 Both approaches are difficult to 
implement. The patient and physician are not likely to be aware 
of variant-level advances in genetic knowledge. Furthermore, 
even if updated information is uncovered it is often delayed. At 
best, a physician or genetic counselor is likely to contact the lab 
for any updates only on an annual basis, yet new information 
might be learned about a reported variant a few weeks after it is 
first reported in the patient. Even if the physician calls one year 
later, months of potential patient benefit are lost. New informa-
tion should not be delayed. 
As a result of these challenges, more pressure is being placed 
upon clinical laboratories to initiate the process of updating 
reports through an amendment process. However, this process 
is equally challenging for laboratories that may not have robust 
systems to manage an update process and currently have no 
mechanism to receive reimbursement for such efforts.
All of these problems will expand rapidly as the total number 
of variants identified in the patient population grows as a result 
of  expanding  testing  volume  and  the  increasing  amount  of 
patient DNA that can be sequenced in each test. New medical 
infrastructure must be established to meet this challenge. The 
first clinical whole-genome sequencing tests have been con-
ducted.6 These tests identify millions of variants per patient—
far beyond what any single organization can curate.
To better demonstrate the scope of this challenge, we have 
tracked the rate of variant classification updates in just one of 
the areas for which our clinical laboratory has offered testing 
for the past six years. The example is HCM. The first clini-
cal test for this disease was introduced in 2004 and as of July 
2011 we had conducted 4,923 tests for this disease, including 
2,644 probands and 2,279 family members. As of this date, 
our database housed 429 HCM variants classified as patho-
genic or likely pathogenic, 244 as unknown significance, and 
296 variants classified as likely benign or benign. An additional 
503 variants are in the lab’s database, having been reported in 
other studies, but remain unclassified because published evi-
dence is not evaluated until a variant is observed in a patient. 
The table found at the following website shows the LMM’s sys-
tem  for  classifying  variants  according  to  available  evidence: 
http://pcpgm.partners.org/sites/default/files/LMM/Resources/
LMM_VariantClassification_05.26.11.pdf.
Over the span of these six years, we have made 214 HCM-
specific classification changes to previously reported variants. 
These  changes  are  primarily  derived  from  new  knowledge 
being gained on these variants as well as some improvements 
to our classification process. Figure 1 shows the volume of spe-
cific class changes for HCM variants. We have grouped these 
changes into three levels of significance (Table 1) depending 
on the likelihood that the classification change would impact 
care of the patient or the understanding of the patient’s disease. 
These changes in variant categories have had an impact on 756 
patient reports. These numbers slightly understate the rate of 
classification changes because each report may be affected by 
multiple classification changes. And this is only one disease. 
The scope of this challenge is daunting to contemplate when 
applied to less well-developed areas of testing, to genes more 
polymorphic than the sarcomere genes of HCM, and to labo-
ratories with much higher volumes than our small academic 
environment.
inFORmAtiOn tecHnOLOGY cAn HeLP
To address the need for more timely and effective communica-
tion of variant updates to treating clinicians, we propose the 
use of information technology. In May 2010, we launched a 
new infrastructure to help solve this dilemma. The application, 
called GeneInsight Clinic, represents an extension of a larger 
in-house-developed software package called the GeneInsight 715 Genetics in medicine  |  Volume 14  |  Number 8  |  August 2012
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Suite, which also includes GeneInsight Lab. The GeneInsight 
Suite supports both germline and somatic testing processes and 
is deployed in multiple laboratory and provider settings across 
many diseases and indications for testing. The system is regis-
tered as a class I exempt medical device. A quality system based 
on 21 CFR 820 regulations is employed to validate the software. 
This reference provides additional information on the system.3 
Figure 2 displays the high-level workflow GeneInsight enables. 
The overall goal of the GeneInsight Clinic provider interface is 
to give health-care providers the ability to fully manage their 
patient  genetic  profiles.  We  have  developed  functionality  to 
support what we feel are four main functions any system must 
have to support the clinician in this new era of personalized 
medicine.
Function 1: deliver reports
This is the most basic function of a provider interface. It enables 
electronic  communication  of  genetic  reports.  An  example 
report can be found in the supplementary information associ-
ated with ref. 3.
Function 2: enable providers to view all genetic tests that 
have been conducted on a patient
Health-care providers should have immediate access to all tests 
that have been conducted on a patient, all clinically assessed 
variants  identified  through  those  tests,  and  the  associated 
reports. We feel it is important that the users be able to use 
a screen to navigate directly to formal laboratory reports, as 
well as pull up additional information on variants. Figure 3 
shows the screen in our current application that displays this 
information. 
Function 3: alert providers when new clinically significant 
information is learned about a variant previously identified 
in one or more of their patients
The  provider  interface  must  manage  the  process  of  notify-
ing providers when new information becomes available on a 
variant previously identified in one or more of their patients. 
As described above, this function is currently important for 
targeted sequencing-based tests that identify VUSs that may 
be later reclassified and other situations where new evidence 
causes  a  laboratory  to  change  a  previous  classification  of  a 
variant. When information changes on a previously reported 
variant, we generate an “alert.” We found it useful to divide 
alerts into three categories, high, medium, and low, as noted 
in Figure 1. We have chosen to send e-mail alerts to providers 
as soon as a high alert is raised on a patient. All other alerts 
are sent in summary e-mails on a periodic basis, with the fre-
quency determined by each clinic. By default, the summaries 
are sent once a week and identify alerts and reports that have 
not yet been reviewed. Based upon user feedback, we are con-
sidering discontinuing the low alerts, which occur when a vari-
ant moves between the likely benign and benign classifications. 
These changes occur frequently and in our view are unlikely to 
impact patient management. GeneInsight Clinic currently only 
supports genotyping and targeted sequencing-based tests. We 
are currently considering how this alerting mechanism should 
be applied to whole-genome- and whole-exome-based testing.
The first step in managing this process involves determining 
what updates should be transmitted. This step can be challeng-
ing because of the need to both account for patient preferences 
and ensure that transmitted updates are relevant to the pro-
viders using the interface. For example, in our test for Marfan 
syndrome we also can uncover a variant that may be associ-
ated with increased cancer risk. Some patients may want their 
cancer risk to be assessed and others may not. Furthermore, 
some physicians ordering Marfan testing may be comfortable 
table 1  Alert categories
Alert categorization sample conditions
High •    Variant of unknown significance reclassified 
to known significance
•    Variant of known significance reclassified to 
unknown significance
•    Benign or likely benign variant reclassified 
to pathogenic or likely pathogenic
•    Pathogenic or likely pathogenic variant 
reclassified to benign or likely benign
•    New disease or pharmacogenomic 
interaction associated with variant
•    Removal of variant association to disease or 
pharmacogenomic effect
Medium •    Likely pathogenic to pathogenic
•    Pathogenic to likely pathogenic
Low •    Likely benign to benign
•    Benign to likely benign
Figure 1  Variant classification changes—Hcm data. Geneticist-approved 
variant classification changes that have occurred since 2004 on variants 
in 11 genes on the HCM CardioChip Test. Only changes that would have 
affected at least one preexisting patient report were counted. The figure also 
reflects only classification changes relative to HCM and does not reflect data 
from other diseases. These 214 changes occurred over ~7 years within our 
knowledge base of 1,472 HCM variants. Over this period, 4,923 tests were 
conducted, including 2,644 probands and 2,279 family members. HCM, 
hypertrophic cardiomyopathy.
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receiving cancer risk information and others may not be. Our 
current approach to managing this issue involves establishing 
an “interpretive scope” for each test when it is reported through 
the  laboratory  infrastructure.  This  interpretative  scope  con-
sists of a list of diseases and/or pharmacogenomic effects that 
should be considered in both report drafting and future alert 
generation. In practice, our infrastructure is set up to generate a 
default interpreted scope to include only the disease areas asso-
ciated with the intended use of the test. It is rare for the labora-
tory to have to adjust the default interpretive scope; however, 
this can occur in Marfan testing. Our Marfan test requisition 
form provides a box that can be checked to indicate whether 
the TGFβR1*6A variant, which may be associated with cancer 
risk, should be included in the report. If the provider indicates 
that he or she would like the patient’s cancer risk to be assessed, 
the laboratory adds this information to the test’s default inter-
pretative scope. The provider interface then respects this scope 
in determining whether future alerts on this variant, or other 
variants that could be reinterpreted later, should be transmitted. 
This basic approach will need to be further generalized as the 
scope of the average genetic test expands and patients are con-
fronted with a wider range of questions regarding what types 
of genetic information they may or may not wish to receive. 
Solutions focused on enabling patients to initially define and 
later update their preferences as to what types of genetic infor-
mation they wish to receive (e.g., carrier status for recessive 
disorders,  risk  for  treatable  late-onset  disorders)  have  been 
proposed.7
Figure 2  Geneinsight workflow. This figure depicts the high-level workflow enabled by GeneInsight. The solid black arrows represent the core reporting 
workflow that occurs each time a test is ordered and a sample received. The dashed arrows show an entirely automated ancillary workflow that occurs when 
the category of a variant is changed. This typically occurs in the course of reporting a test but can also occur independent of a test order. As a high-level view, 
this figure does not represent all system-level communication that occurs during the reporting process.
GeneInsight Lab
Test ordered/
sample collected
Sample analyzed/
variants identified
Laboratory
Information
Management
System (LIMS)
Report generation tool
Genetic
counselors Geneticists
Edited
reports
Finalized
reports
Auto-drafted
reports
Knowledge base
GeneInsight Clinic
(ordering organization)
New
report
Case history
Ordering
organization
clinician(s)
GeneInsight Clinic
(different organization A)
Case history
Organization
A
clinician(s)
Organization
B
clinician(s)
Ordered
report
delivered
GeneInsight Clinic
(different organization B)
Case history
Case histories
automatically
updated
Clinicians notified
of new information
relevant to
previous reports
Genelnsight workflow717 Genetics in medicine  |  Volume 14  |  Number 8  |  August 2012
Updating knowledge on reported genetic variants  |  ARONSON et al  special article
When we launch a new GeneInsight Clinic, the system ana-
lyzes past reports and generates alerts for each reported variant 
whose classification has changed. This can result in a material 
number of alerts. We calculated a launch-time alert rate for each 
clinic by dividing the number of medium and high alerts gener-
ated at launch by the number of cases initially loaded into the 
clinic. Rates ranged from 3.9% to 11.2% of cases. However, after 
the initial launch is complete, the alert frequency slows consider-
ably. To calculate a monthly alert rate, we began by summing the 
total number of months each report resided in the system. We 
then determined the total number of high and medium alerts 
generated on these reports after the GeneInsight Clinics were 
launched. Dividing the total post launch alerts by the number 
of “report months” generated an average monthly alert rate of 
0.33%. As tests mature, the variant knowledge becomes increas-
ingly stable and the alert rate decreases. However, the need for 
alerting processes is never eliminated. Currently, 17% of clini-
cally significant variants we identify in HCM patients are novel 
even after we have tested over 2,000 probands across 6 years. 
As a result, a large pool of variants continues to be ripe for new 
knowledge gains. In addition, when new DNA regions are added 
to a test, the knowledge accumulation process begins anew. 
We  have  found  it  important  to  provide  supporting  evi-
dence for the classification changes that generate these alerts. 
In our case, this evidence is entered into the text description 
of  the  variant  that  is  used  in  the  normal  reporting  system. 
GeneInsight  Clinic  applications  are  connected  to  reporting 
laboratory GeneInsight Lab applications. The laboratory infra-
structure contains a knowledge base that tracks variant classifi-
cations relative to diseases or pharmacogenomic effects. When 
this variant text is updated in the GeneInsight Lab system, it 
is then automatically incorporated into each patient’s genetic 
profile within the treating clinician’s GeneInsight Clinic appli-
cation. The system allows laboratory staff (e.g., genetic coun-
selors, fellows, residents) to propose changes to these classifica-
tions. These proposed changes are then approved or rejected 
by users with appropriate permissions, typically geneticists or 
medical  directors.  Approved  changes  are  then  automatically 
sent to connected GeneInsight Clinic applications that generate 
patient-specific alerts to clinicians. 
The  system  provides  updated  information  through  e-mail 
notifications and screen updates. E-mail notifications do not 
contain patient-specific information but rather contain links 
that direct the user to the patient’s screen after logging in to 
the application. New reports are not issued because this would 
require geneticists to sign out a revised report for each affected 
patient. Our goal has been to make the update process eco-
nomically feasible in an environment where these updates are 
not reimbursed. Because alerts are triggered when geneticists 
update variant-level information, usually as a result of analy-
sis done in the course of reporting a case, generating updates 
often does not require additional laboratory effort. This infra-
structure’s effect on clinical workflow and usability is currently 
being studied through a National Library of Medicine grant 
(R1LM010526). Thus far, clinicians have not requested amended 
reports in response to updates. This was a welcome develop-
ment. Although the LMM is able to generate amended reports 
for a limited number of cases, we would not have the resources 
to provide amended reports without charge each time a knowl-
edge update is issued. Clinician users have provided us with 
feedback indicating that the system provides them with useful 
and timely information critical to the care of their patients. 
Figure 3  the Geneinsight clinic interface. This interface image provides an example of how a screen can be assembled to manage clinical genetic test 
results. Users can navigate to this screen either by searching for a patient or by clicking patient-specific links in alert e-mails. (These e-mails contain no protected 
health information.) From this screen, users can pull up the report associated with each case or obtain additional information when clicking on a specific 
variant. They can also see whether the laboratory has reclassified a variant since the test was originally reported. Boxes have been added for emphasis and do 
not appear on the actual screen. (Adapted from ref. 3.)
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There is always the risk that an alert will be generated for a 
patient who is no longer being seen by the clinic. To date, we are 
only aware of two cases in which this situation has arisen. The 
system has been deployed to clinics associated with academic 
medical centers that likely have more stable patient populations 
than typical clinics. This may be a larger issue for community 
practices. Ultimately, standards and systems for addressing this 
issue will be required. Electronic Health Record (EHR) integra-
tions may be able to assist if EHRs develop functionality to main-
tain  associations  between  clinicians  and  patients.  Geneticists 
and treating clinicians have also suggested that we could enable 
patients to specify an e-mail address where they can be contacted 
if they are no longer being seen by the ordering clinician. 
Function  4:  allow  providers  a  means  of  searching  for 
  patients,  within  their  patient  population,  who  harbor  a 
particular variant
At  times  a  provider  may  decide,  independent  of  system-
  generated alerts, to review the care of all patients who harbor a 
certain variant or set of variants. This may occur if they become 
aware of a clinical association independent of the reporting lab. 
This situation can be supported by providing clinicians a robust 
means of searching their patient population for patients that 
harbor the variant. 
This  functionality  also  has  powerful  research  uses.  There 
has been some concern expressed that clinicians could easily 
use the system for research purposes without proper approval. 
To protect against this situation, by default we restrict search 
results to patients for whom the user is listed as an ordering 
provider on the report. If the user desires to search for reports 
for which they are not listed as an ordering provider, he or she 
must supply a reason for doing the search. If the user specifies 
that the search is being done for research purposes, he or she 
must enter an institutional review board protocol number and 
approval date. All searches are logged and therefore auditable. 
Every provider organization has its own database schema con-
taining only its own patient records, so searches cannot return 
another institution’s records.
There are situations in which the above search restrictions 
could impede legitimate clinical searches. For example, when 
clinicians are covering for one another they may need to access 
reports that they did not order. In these cases, we allow the user 
to specify that he or she is doing an expanded search for clinical 
purposes.
ResULts seen tHROUGH cURRent  
dePLOYments
GeneInsight Clinic has been deployed to a total of five clin-
ics  thus  far:  Brigham  and  Women’s  Hospital  Cardiology, 
Massachusetts General Hospital Cardiology, and Massachusetts 
General  Hospital  Genetics  (Boston,  MA);  University  of 
Michigan Cardiology (Ann Arbor, MI); and the Fred A. Litwin 
& Family Centre for Clinical Genetics and Genomic Medicine 
(Toronto, Canada). These clinics are currently capable of receiv-
ing reports and alerts from the Partners HealthCare Center for 
Genetic Medicine’s LMM. More clinics are being established. 
We are also working to establish connections that will allow 
other GeneInsight Lab users to send results into GeneInsight 
Clinics as well. 
As of 16 August 2011, the deployed GeneInsight Clinic appli-
cations were managing a total of 2,174 reports. A total of 321 
alerts on 254 patients had been sent. (More than 1 alert was 
issued for some patients.) Of these alerts, 124 were high alerts 
and 57 were medium alerts. As noted above, these alerts provide 
potentially critical new information to clinicians that is very 
difficult to obtain through other means. These numbers do not 
include alerts for information that the laboratory had already 
updated in the past through manual report amendments. These 
alerts were generated based on a relatively small number of 
highly targeted sequencing tests. Even so, without this type of 
information technology infrastructure, it would be difficult to 
maintain a process capable of generating and delivering these 
alerts without materially increasing the cost of testing. 
LinKinG tO eHRs
We chose to initially deploy GeneInsight Clinic as an inde-
pendently hosted, Web-accessible system because of the time 
required to integrate with EHRs. This requires clinicians to log 
in to a separate system when they receive an e-mail alert. We 
informally surveyed several clinicians before making this deci-
sion. These clinicians indicated that the benefits of patient-spe-
cific variant classification change alerts significantly outweighed 
the need to use a separate genetic health record system, and 
they advised us to work to deploy the alerting functionality as 
quickly as possible. However, truly widespread deployment of 
this type of functionality will require EHR integration. These 
integrations are also needed to provide clinical decision sup-
port based on the integration of clinical and genetic data. We 
are  currently  working  on  integrations  to  both  the  Partners 
HealthCare  and  the  Intermountain  HealthCare  EHRs.  We 
would be very interested in working with other institutions 
interested in addressing these issues.
It will be important for the EHR environment to provide inte-
grated clinical decision support that takes into account both 
the patient’s clinical data and their genomic profile. Interfaces, 
capable of delivering structured case data, including identified 
variants and associated alerts, will need to be constructed to 
enable this support. For this reason, it is important that clini-
cian facing genetic infrastructure maintain these data.
Clinical whole-exome and whole-genome sequencing tests 
have  been  launched  and  will  need  to  be  electronically  sup-
ported.  Initially,  we  will  only  load  validated,  clinically  sig-
nificant variants into GeneInsight Clinic. However, the clini-
cal uses for whole-exome/genome sequence will likely grow 
rapidly, creating the need to load all identified variants, along 
with appropriate quality metrics, into the system. The hard-
ware requirements associated with scaling the infrastructure in 
this way are currently unclear. We anticipate that only variants 
and quality scores will be loaded into the system, whereas all 
raw and intermediate supporting data will be retained by the 719 Genetics in medicine  |  Volume 14  |  Number 8  |  August 2012
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reporting laboratory systems, to the extent they are retained at 
all. This will reduce the GeneInsight Clinic resource consump-
tion but the database infrastructure required to store, cross-
index, and back up roughly 3 million variants per patient will 
still be significant. 
cOncLUsiOn
As a growing number of sequencing tests are ordered and the 
average number of base pairs sequenced per test increases, 
the number of VUSs identified in the patient population will 
grow  rapidly.  The  need  for  infrastructure  to  keep  provid-
ers up to date on the meaning of these variants will become 
increasingly critical. However, it takes time to establish inter-
organizational information technology infrastructure. Given 
the speed at which the molecular diagnostic testing industry 
is evolving, we must start setting up the required informa-
tion infrastructure now. If we delay, the lack of information 
technology support may ultimately constrain the growth of 
molecular   diagnostic testing and the widespread adoption of 
  personalized medicine.
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